Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous peripheral blood-derived CD34+ cells
- Development stage
- Discontinued
- Lead developer
- Lisata Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous peripheral blood-derived CD34+ cells, also known as CLBS119, are a cell therapy product consisting of hematopoietic stem/progenitor cells isolated from a patient's own (autologous) peripheral blood. Developed by Caladrius Biosciences, this therapy is being investigated for the repair of lung damage in patients who have suffered severe COVID-19 infection. The mechanism of action involves the regenerative and vascular repair properties of CD34+ cells, which have shown evidence in preclinical and clinical studies to restore microvasculature and promote tissue regeneration in damaged organs. In the context of COVID-19-induced pulmonary damage, CLBS119 aims to regenerate blood vessels damaged by SARS-CoV-2 infection, thereby improving lung function and reducing or eliminating the need for supplemental oxygen[1][3][4][5][6].
- Other names
- CD34+ cells
Beyond the preview
Go deeper on autologous peripheral blood-derived CD34+ cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous peripheral blood-derived CD34+ cells.